Core Viewpoint - The reclassification of cannabis from Schedule I to Schedule III under the U.S. Controlled Substances Act is a significant milestone that recognizes its medical use and is expected to facilitate clinical research and partnerships for MediPharm Labs [1][4][10]. Industry Impact - The reclassification is anticipated to accelerate cannabis-related medical research by removing barriers that have historically limited U.S. clinical trials, allowing for standardized medical-grade cannabis access [4][5]. - The change may lead to increased interest from institutional investors in research-oriented cannabis companies, as regulatory barriers evolve [10]. Company Positioning - MediPharm Labs is strategically positioned to benefit from this reclassification due to its FDA site registration, Drug Establishment License, and experience in supplying clinical trial materials to the U.S. [2][6]. - The company has a proven track record, having supplied products for over 10 active clinical trials, including significant studies funded by the U.S. National Institutes of Health [7][8]. Research and Development Opportunities - The reclassification is expected to create a pipeline of researchers ready to advance clinical trials and evaluate compliant active pharmaceutical ingredient suppliers [5]. - MediPharm Labs has developed international licensing and regulatory expertise, enabling it to support new research initiatives that require pharmaceutical-grade standards [6][9]. Future Growth Potential - The company anticipates that the reclassification will strengthen its ability to expand U.S. clinical trial partnerships and facilitate significant growth in clinical research [3][10]. - MediPharm Labs' unique combination of experience and regulatory credentials positions it to immediately support new research initiatives in the U.S. and globally [8][9].

VANCOUVER, British Columbia, Dec. 18, 2025 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN, FSE: 85W0, OTC PINK: HYTNF) (“HYTN” or the “Company”), a pharmaceutical-grade cannabis manufacturer, acknowledges the announcement by the United States administration issuing an executive order directing federal agencies to initiate the reclassification of cannabis to a Schedule III controlled substance under U.S. federal law. The executive order directs the relevant federal authorities to advance the administra ...

Core Viewpoint - MediPharm Labs Corp. has successfully dismissed a defamation claim against its CEO and Chairman, reinforcing its legal standing and credibility in the market [1][2][3]. Legal Developments - The Superior Court of Justice in Ontario dismissed a $50 million defamation claim against CEO David Pidduck and Chairman Chris Taves, which was initiated by Apollo Technology Capital Corporation and Nobul Technologies Inc. [1][3] - The court's decision followed a previous dismissal of a related conflict of interest claim against the company's litigation counsel [2]. - The court found that the plaintiffs failed to provide evidence of harm caused by the April 29 letter, which was deemed typical of legal correspondence in such circumstances [3]. Company Background - MediPharm Labs specializes in the development and manufacture of pharmaceutical-quality cannabis concentrates and active pharmaceutical ingredients, operating under Good Manufacturing Practices [5]. - The company received a Pharmaceutical Drug Establishment License from Health Canada in 2021, making it the only North American company with a commercial-scale GMP license for extracting multiple natural cannabinoids [6]. - In 2023, MediPharm expanded its market reach by acquiring VIVO Cannabis Inc., enhancing its presence in Canada, Australia, and Germany [7].

Core Viewpoint - MediPharm Labs Corp. is set to release its third quarter financial results for the period ending September 30, 2025, on November 13, 2025, before market opening [1] Group 1: Financial Results Announcement - The company will host a conference call and webcast on November 13, 2025, at 10:00 a.m. Eastern time to discuss its financial results [2] - Participants are encouraged to dial in approximately 15 minutes before the start of the call [3] Group 2: Company Overview - Founded in 2015, MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates and advanced derivative products [5] - The company operates a Good Manufacturing Practices certified facility with ISO standard-built clean rooms, focusing on delivering pure and precision-dosed cannabis products [5] - In 2021, MediPharm Labs received a Pharmaceutical Drug Establishment License from Health Canada, becoming the only company in North America with a commercial-scale domestic GMP License for the extraction of multiple natural cannabinoids [6] - In 2023, MediPharm acquired VIVO Cannabis Inc., expanding its reach to medical patients in Canada, Australia, and Germany [7]

Core Viewpoint - RAMM Pharma Corp. is proposing a US$5 million investment in Global South for a 10% equity interest, subject to minority shareholder approval at a special meeting scheduled for November 12, 2025 [1][4]. Transaction Description - The proposed investment values Global South at US$50 million post-investment, with RAMM granted a call option to acquire an additional 15% equity interest, potentially increasing total ownership to 25% at a future valuation of US$400 million [4]. - The transaction is classified as a "related party transaction" under Multilateral Instrument 61-101 due to Global South being wholly owned by the CEO of RAMM, Jackie Peter Burnett, who will be excluded from voting [4]. - The company currently lacks sufficient funds to complete the transaction but plans to monetize assets or obtain financing to raise the necessary capital [4]. - The purchase price for the 10% interest remains fixed at US$5 million, regardless of any changes in Global South's valuation before the transaction's completion [4]. Background of the Transaction - The Special Committee of RAMM's Board was formed to review the transaction, engaging an independent valuator to assess the strategic rationale and financial forecasts of Global South [6][8]. - The Fair Market Value Report concluded that the transaction is fair from a financial perspective for minority shareholders [6][8]. - Global South is developing the GSDC stablecoin, which is pegged to a diversified basket of BRICS+ fiat currencies and backed by real-world assets to mitigate inflationary pressures [8]. Company Overview - RAMM Pharma operates in cannabinoid pharmacology and product formulation for cannabis-based pharmaceuticals, with a diversified international production and sales platform [7]. - The company has subsidiaries in Italy and Poland, focusing on extraction, processing, and distribution of hemp products [9].

Company Overview - Vertanical is a Munich-based pharmaceutical company developing a cannabinoid-based extract, Ver-01, aimed at treating chronic pain, with hopes for approval in the EU and the U.S. [1][4] - The founder, Clemens Fischer, has invested over $250 million of his own money into Vertanical since its establishment in 2017 [4][10]. Product Development - Ver-01 has successfully passed Phase III clinical trials in Germany, showing effectiveness greater than opioid painkillers with fewer side effects and no evidence of addiction [4][6]. - The company is awaiting marketing approval from German and Austrian authorities, with plans to apply for broader EU authorization and to launch Phase III trials in the U.S. by 2026 [4][10]. Market Potential - The U.S. cannabis industry is valued at $32 billion in 2024, but the focus for Vertanical is on the pharmaceutical approval process rather than the recreational market [3][6]. - The market for non-opioid pain relievers is significant, with 125 million opioid prescriptions written in the U.S. in 2023, representing a market worth approximately $20 billion annually [6][7]. Competitive Landscape - Vertanical aims to be the first non-opioid chronic pain treatment worldwide, competing with existing alternatives and addressing the urgent need for effective pain management solutions [5][6]. - Other companies, such as the Stanley Brothers, are also developing cannabis-derived drugs, indicating a growing interest in FDA-approved cannabis medicines [8][9]. Financial Projections - If approved, Ver-01 is expected to achieve blockbuster status, with projected revenues exceeding $2 billion within the first two years on the market [11][12]. - The average cost to bring a new drug through the FDA approval process is around $880 million, with a high failure rate, emphasizing the financial risks involved [10][11].

Core Insights - Avicanna Inc. reported Q2 2025 results, highlighting growth in its commercial channels and achieving positive adjusted EBITDA for the first half of 2025, indicating operational efficiency and financial discipline [2][5]. Financial Highlights - Revenue for Q2 2025 was $6.16 million, a 1% increase year-over-year, while revenue for the six-month period was $12.48 million, reflecting a 1% decrease compared to the same period in 2024 [5]. - Gross profit for Q2 was $3.13 million, with a gross margin of 51%, and for the six-month period, gross profit totaled $6.73 million with a margin of 54%, up from 47% in the prior-year periods [5]. - Adjusted EBITDA showed a loss of $0.25 million for Q2 but a gain of $0.18 million for the six-month period, marking an improvement from losses of $0.44 million and $0.42 million in the same periods of 2024 [5]. Corporate Highlights - The company expanded its product offerings, ending Q2 with 50 commercial SKUs and 147 listings, representing a 19% increase in SKUs and a 9% increase in listings from Q1 2025 [5]. - Avicanna sold 50,789 units in Q2, a 21% increase compared to the same period in 2024 [5]. - The company announced a sponsorship for a Phase II clinical study on osteoarthritis pain, which is its first placebo-controlled, blinded randomized multicenter trial [5]. - A symposium on cannabinoid-based medicine was held in June 2025, focusing on research and clinical applications, attended by key opinion leaders and healthcare providers [5]. - Avicanna received a new patent from the US Patent and Trademark Office for a topical cannabinoid composition aimed at treating skin conditions [5][6].

Core Viewpoint - MediPharm Labs Corp. is set to release its second quarter financial results for the period ending June 30, 2025, on August 14, 2025, before market opening [1] Group 1: Financial Results Announcement - The company will host a conference call and webcast on August 14, 2025, at 10:00 a.m. Eastern time to discuss its financial results [2] - Participants are encouraged to dial in approximately 15 minutes before the start of the call [3] Group 2: Company Overview - Founded in 2015, MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates and advanced derivative products [5] - The company operates a Good Manufacturing Practices certified facility with ISO standard-built clean rooms [5] - MediPharm Labs has invested in a research-driven team and state-of-the-art technology for the delivery of precision-dosed cannabis products [5] Group 3: Regulatory and Market Expansion - In 2021, MediPharm Labs received a Pharmaceutical Drug Establishment License from Health Canada, becoming the only company in North America with a commercial-scale domestic Good Manufacturing Practices License for the extraction of multiple natural cannabinoids [6] - In 2023, the company acquired VIVO Cannabis Inc., expanding its reach to medical patients in Canada, Australia, and Germany [7]

Core Insights - MediPharm Labs Corp. has launched a new Shake & Puff CBN THC Nighttime Inhaler in Canada, expanding its CBN oil product portfolio and building on the success of its earlier THC Inhaler [1][2] Product Overview - The new metered dose inhaler provides a precise formulation of minor cannabinoid CBN and THC in a smoke-free format, designed for nighttime use with a fast onset experience [2][4] - The inhaler format ensures precision and repeatability, offering a familiar and discreet option similar to asthma inhalers, with no lingering smell or by-products [4][11] Strategic Positioning - The launch is part of MediPharm's strategy to deliver innovative, pharma-grade cannabinoid products globally, positioning the company to lead in smoke-free, precisely dosed formats that align with consumer wellness trends and medical needs [2][5] - The company plans to expand its inhaler offerings with additional CBD and CBG options in the future, continuing to lead in pharma-grade cannabinoid innovation [5] Company Background - MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates and advanced derivative products, operating in a GMP certified facility [6] - The company received a Pharmaceutical Drug Establishment License from Health Canada in 2021, becoming the only North American company with a commercial-scale GMP License for the extraction of multiple natural cannabinoids [7] - In 2023, MediPharm acquired VIVO Cannabis Inc., enhancing its reach to medical patients in Canada and expanding into international markets [8]

Core Viewpoint - MediPharm Labs Corp. has received a recommendation from Glass Lewis to support its nominees for the Board of Directors in the upcoming shareholder meeting on June 16, 2025 [1][2] Group 1: Shareholder Voting - Glass Lewis is the second independent proxy advisory firm to recommend voting for the Company's nominees, following a similar recommendation from ISS [2] - MediPharm urges shareholders to vote using the GREEN proxy to support all nominees and resolutions, with votes due by 3:00 p.m. Eastern time on June 13, 2025 [3] - Shareholders are encouraged to contact their broker for their control number to ensure their vote is counted [4] Group 2: Company Overview - Founded in 2015, MediPharm Labs specializes in the development and manufacture of pharmaceutical-quality cannabis concentrates and products [5] - The company received a Pharmaceutical Drug Establishment License from Health Canada in 2021, making it the only North American company with a commercial-scale GMP License for cannabinoid extraction [6] - In 2023, MediPharm acquired VIVO Cannabis Inc., expanding its reach to medical patients in Canada, Australia, and Germany [7]